Synthesis and molecular docking studies of novel 2-chloro-pyridine derivatives containing flavone moieties as potential antitumor agents

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 14, 2010, Pages 4163-4167

  Liu, Xin Hua ^a,b   Liu, Hui Feng ^b   Shen, Xu ^a   Song, Bao An ^c   Bhadury, Pinaki S ^c   Zhu, Hai Liang ^a,b   Liu, Jin Xing ^b   Qi, Xing Bao ^d  

^a NANJING UNIVERSITY   (China)

^b ANHUI UNIVERSITY OF TECHNOLOGY   (China)

^c GUIZHOU UNIVERSITY   (China)

^d CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

2 Chloro pyridine; Antitumor agent; Flavone; Molecular docking; Synthesis

Indexed keywords

1 (5 (2 ((6 CHLOROPYRIDIN 3 YL)METHOXY)PHENYL) 3 METHYL 4,5 DIHYDROPYRAZOL 1 YL); 3 ((6 CHLOROPYRIDIN 3 YL)METHOXY) 2 PHENYL 4H CHROMEN 4 ONE; 7 ((6 CHLOROPYRIDIN 3 YL)METHOXY) 5 HYDROXY 2 PHENYL 4H CHROMEN 4 ONE; FLUOROURACIL; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; SIMULATION; STOMACH CANCER; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FLAVONES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PYRIDINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 77953871282     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.05.080     Document Type: Article

References (22)

1. Wright W.E., and Shay J.W. Curr. Opin. Genet. Dev. 11 (2001) 98
2. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., and Wright W.E. Science 279 (1998) 349
3. Andrew J.G., Anthony P.S., and Emmanuel S. Nature 455 (2008) 633
4. Hanket T., Brunne R.M., Miller H., and Reichel F. Angew. Chem., Int. Ed. 38 (1999) 643
5. Gavin D.H. Tetrahedron 60 (2004) 6043
6. Kim D.S.H.L., Ashendel C.L., Zhou Q., Chang C.T., Lee E.S., and Chang C.J. Bioorg. Med. Chem. Lett. 8 (1998) 2695
7. Tipparaju S.K., and Joyasawal S. Bioorg. Med. Chem. Lett. 18 (2008) 3565
8. Hanessian S., Simard D., Bayrakdarian M., Therrien E., and Nilsson I. Bioorg. Med. Chem. Lett. 18 (2008) 1972
9. Neuhouser M.L. Nutr. Cancer 50 (2004) 1
10. Min L.W. Cancer Treat. Rev. 35 (2009) 57
11. Yukihiro A., Tomohiro I., Kenji O., Munekazu I., and Yoshinori N. Bioorg. Med. Chem. 16 (2008) 2803
12. Jared R., Mays S.A., Hill J.T., Moyers B.S., and Blagg J. Bioorg. Med. Chem. 18 (2010) 249
13. Hsu S., Singh B., and Schuster G. Oral Oncol. 40 (2004) 461
14. Elattar T.M., and Virji A.S. Anticancer Res. 20 (2000) 3459
15. Werbitzky, O.; Studer. P. U.S. Patent 6022974, February 8, 2000; Chem. Abstr. 1997, 120, 134302.
16. Liu X.H., Cui P., Song B.A., Bhadury P.S., Zhu H.L., and Wang Sh.F. Bioorg. Med. Chem. 16 (2008) 4075
17. Prakash O., Kumar R., and Parkash V. Eur. J. Med. Chem. 43 (2008) 435
18. 4: C, 64.17; H, 3.59; N, 5.54. Found: C, 64.00; H, 3.81; N, 5.79.
19. 50 value was defined as the concentration at which 50% of the cells could survive.
20. Chen X.Y., Plasencia C., Hou Y., and Neamati N. J. Med. Chem. 48 (2005) 1098
21. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., and Shay J.W. Science 266 (1994) 2011
22. Han H., Hurly L.H., and Salazar M. Nucleic Acids Res. 27 (1999) 537